Skip to main content

Table 1 Patients, tumor, and systemic therapy characteristics

From: IOERT versus external beam electrons for boost radiotherapy in stage I/II breast cancer: 10-year results of a phase III randomized study

  IOERT boost arm EBRT boost arm p value
Women in each arm 125 (51%) 110 (49%)  
Median age (range) 56.3 years (29–75) 56.2 years (34–75) 0.96**
Menopausal status 0.81*
 Pre 37 (30%) 31 (28%)  
 Post 88 (70%) 79 (72%)  
Disease laterality 0.73*
 Right breast 54 (43%) 50 (45%)  
 Left breast 71 (57%) 60 (55%)  
Histology 0.46*
 IDC 61 (49%) 59 (54%)  
 ILC 17 (14%) 11 (10%)  
 DCIS 3 (1.4%) 3 (2.6%)  
 IDC+DCIS 32 (26%) 24 (22%)  
 Medullary 6 (5%) 4 (3.5%)  
 ILC+ILCS 5 (4%) 5 (4.4%)  
 Missing 1 (0.6%) 4 (3.5%)  
Pathologic T stage 0.38*
 pT1 96 (77%) 79 (72%)  
 pT2 28 (22%) 22 (20%)  
 pT3–pT4 1 (1%) 1 (1%)  
 Missing 0 8 (7%)  
Pathologic N stage 0.55*
 pN0 82 (65%) 68 (62%)  
 pN1 38 (30%) 32 (29%)  
 pN2 2 (2.1%) 1 (1%)  
 pN3 1 (0.8%) 1 (1%)  
 Missing 2 (2.1%) 8 (7%)  
Adjuvant chemotherapy 0.61*
 Yes 37 (30%) 36 (33%)  
 Not 85 (68%) 64 (58%)  
 Missing 3 (2%) 10 (9%)  
Hormone therapy 0.66*
 Yes 105 (84%) 90 (81%)  
 Not 19 (15%) 12 (11%)  
 Missing 1 (1%) 8 (8%)  
  1. Abbreviations: IDC, invasive ductal carcinoma; ILC, invasive lobular carcinoma; DCIS, ductal carcinoma in situ
  2. **Mann-Whitney test
  3. *Chi-square test